Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease

Journal of the American Society of Nephrology

Volumn 13, Issue 1, 2002, Pages 170-176

  Kielstein, J T ^a   Boger R H ^a   Bode Boger S M ^a   Frolich J C ^a   Haller, H ^a   Ritz, E ^a   Fliser, D ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CHOLESTEROL; CREATININE; DIMETHYLARGININE; HOMOCYSTEINE; NITRIC OXIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INULIN CLEARANCE; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MORTALITY; PRIORITY JOURNAL; UREMIA;

EID: 0036137591     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Cardiovascular risk factors in chronic renal failure and hemodialysis populations
2. Atherosclerosis and arteriosclerosis in chronic renal failure
3. Premature cardiovascular disease in chronic renal failure
4. Apolipoprotein B-containing lipoproteins in renal failure: The relation to mode of dialysis
5. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure
6. Hyperhomocystinemia in chronic renal disease
7. Is NO an endogenous antiatherogenic molecule?
8. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
9. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure
10. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease
11. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease
12. Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis
13. Independent association of asymmetric dimethylarginine (ADMA) with presence and severity of coronary artery disease
14. Does ADMA cause endothelial dysfunction?
15. Asymmetric dimethylarginine (ADMA): An endogenous inhibitor of NO synthase predicts mortality in patients with end-stage renal disease
16. Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients
17. Indices of activity of the nitric oxide system in hemodialysis patients
18. NG, NG-dimethylarginine and NG, N′G-dimethylarginine in renal insufficiency
19. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease
20. Renal functional reserve in healthy elderly subjects
21. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits
22. Fully enzymatic inulin determination in small volume samples without deproteinization
23. Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease
24. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease
25. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction
26. Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox
27. Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease
28. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial
29. Identification of two human dimethyl-arginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases
30. Purification and properties of a new enzyme, NG, NG-dimethylarginine dimethylaminohydrolase, from rat kidney
31. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney
32. Renal expression of constitutive NOS and DDAH: Separate effects of salt intake and angiotensin
33. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia
34. Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase
35. Regional and cardiac haemodynamic effects of dimethyl-L-arginine and their reversibility by vasodilators in conscious rats
36. Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model
37. Renal failure: A state of nitric oxide deficiency?